Immune thrombocytopenic purpura

DaVita Recognizes Nephrology Nurses with DAISY Award

Retrieved on: 
Wednesday, May 10, 2023

DENVER, May 10, 2023 /PRNewswire/ -- DaVita Inc. today announced that 56 of its nephrology nurses were honored with the DAISY Award® for Extraordinary Nurses during National Nurses Week. The award is part of the DAISY Foundation's mission to recognize nurses who provide outstanding, compassionate care in more than 5,800 health care facilities across the country.

Key Points: 
  • today announced that 56 of its nephrology nurses were honored with the DAISY Award® for Extraordinary Nurses during National Nurses Week.
  • The award is part of the DAISY Foundation's mission to recognize nurses who provide outstanding, compassionate care in more than 5,800 health care facilities across the country.
  • "In Italian, DaVita means 'to give life,' which is exactly what our nurses do every day," said Tina Livaudais, chief nursing officer for DaVita.
  • The kind of work the nurses at DaVita are called on to do every day epitomizes the purpose of the DAISY Award."

SignatureCare Emergency Center Honors 1st DAISY Award Recipient for Nursing Excellence, Extraordinary Compassionate Care to Patients and their Families

Retrieved on: 
Wednesday, August 31, 2022

HOUSTON, Aug. 31, 2022 /PRNewswire-PRWeb/ -- SignatureCare Emergency Center has awarded its 1st DAISY Award For Extraordinary Nurses to Bridget Castillo, RN, a Staff Nurse at the company's Odessa facility.

Key Points: 
  • HOUSTON, Aug. 31, 2022 /PRNewswire-PRWeb/ -- SignatureCare Emergency Center has awarded its 1st DAISY Award For Extraordinary Nurses to Bridget Castillo, RN, a Staff Nurse at the company's Odessa facility.
  • The company announced this week that Castillo was chosen for the award for giving extraordinary and compassionate care to her patients and families daily.
  • According to Rhonda Abbe, SignatureCare Emergency Center's Director of Operations, SignatureCare's purpose for giving the DAISY Award For Extraordinary Nurses is to honor its emergency room nurses who go above and beyond to give extraordinary and compassionate care to patients and their families.
  • "Our nurses do a great job caring for our patients, but sometimes, we witness extraordinary and compassionate care and service.

LiveOnNY Staff Recognized for Saving Lives Through Organ and Tissue Donation with the Prestigious DAISY Team Award for Extraordinary Nurses

Retrieved on: 
Tuesday, May 10, 2022

NEW YORK, May 10, 2022 /PRNewswire/ -- LiveOnNY was presented with the prestigious DAISY Team Award for Extraordinary Nurses in recognition of the myriad ways the organ procurement organization partners with Mount Sinai Queens to go above and beyond to honor, save and change lives through organ and tissue donation. The individual award was presented to Brian Papszycki, Director of Hospital Services at LiveOnNY and the team award was presented to LiveOnNY staff and also to members of the Mount Sinai Queens emergency department, intensive care, operating, perioperative and palliative care teams for working as an interdisciplinary team to support organ and tissue donation.

Key Points: 
  • We could not do what we do without the interdisciplinary teams that partner with us every day in our hospitals to change and save lives through organ and tissue donation.
  • I am proud of the LiveOnNY and Mount Sinai Queens staff for working hand-in-hand to deliver the gift of life and honor our organ donor heroes.
  • The DAISY Team Award started in 1999 and is an international recognition given by over 5,000 healthcare organizations today.
  • LiveOnNY is a nonprofit, federally designated organ procurement organization (OPO) dedicated to saving lives, providing comfort, and strengthening legacies through organ, eye, and tissue donation.

DaVita Honors Extraordinary Nurses with DAISY Awards

Retrieved on: 
Tuesday, May 10, 2022

DENVER, May 10, 2022 /PRNewswire/ -- DaVita today announced that 56 of its nephrology nurses were honored with the DAISY Award® for Extraordinary Nurses during National Nurses Week. The award is part of the DAISY Foundation's™ mission to recognize the outstanding, compassionate care that nurses provide to patients and families every day.

Key Points: 
  • DENVER, May 10, 2022 /PRNewswire/ -- DaVita today announced that 56 of its nephrology nurses were honored with the DAISY Award for Extraordinary Nursesduring National Nurses Week.
  • "At DaVita, we have an unwavering commitment to nursing excellence," says Tina Livaudais, chief nursing officer for DaVita.
  • I'm proud to celebrate this achievement and the many ways DaVita nurses positively impact dialysis communities across the country."
  • The kind of work the nurses at DaVita are called on to do every day epitomizes the purpose of the DAISY Award."

Zai Lab Partner argenx Announces Positive Phase 3 Data from ADVANCE Trial of VYVGART® (efgartigimod alfa-fcab) in Adults with Primary Immune Thrombocytopenia

Retrieved on: 
Thursday, May 5, 2022

SHANGHAI, China and SAN FRANCISCO and CAMBRIDGE, Mass., May 05, 2022 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that the company’s partner argenx (Euronext & Nasdaq: ARGX) reported positive data from the Phase 3 ADVANCE trial of VYVGART® (efgartigimod alfa-fcab).

Key Points: 
  • In adults with primary ITP, ADVANCE met its primary endpoint demonstrating that a higher proportion of chronic ITP patients receiving VYVGART achieved a sustained platelet count response compared to placebo.
  • ADVANCE is the first Phase 3 clinical trial of a neonatal Fc receptor (FcRn) blocker in ITP.
  • Additional secondary endpoint data from the ADVANCE trial are consistent with primary and secondary platelet-derived endpoints and provide additional context on metrics that often drive treatment decisions.
  • The Phase 3 ADVANCE trial was a randomized, double-blind, placebo-controlled, multicenter, global trial evaluating the efficacy and safety of VYVGART in adult patients with chronic or persistent primary ITP.

Rallybio Announces Clinical Proof of Concept for RLYB211, an Anti-HPA-1a Antibody for the Prevention of Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT)

Retrieved on: 
Friday, July 2, 2021

RLYB211, a polyclonal anti-HPA-1a antibody, is being evaluated for the prevention of Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT), a potentially life-threatening rare disease that can cause uncontrolled bleeding in fetuses and newborns.

Key Points: 
  • RLYB211, a polyclonal anti-HPA-1a antibody, is being evaluated for the prevention of Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT), a potentially life-threatening rare disease that can cause uncontrolled bleeding in fetuses and newborns.
  • These data reinforce our conviction in our approach as we prepare to move RLYB212 into the clinic.
  • Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT) is a potentially life-threatening rare disease that can cause uncontrolled bleeding in fetuses and newborns.
  • Rallybio is headquartered in New Haven, Connecticut, with an additional facility at the University of Connecticuts Technology Incubation Program in Farmington, Connecticut.

Sobi and Platelet Disorder Support Association (PDSA) launch digital diary app for people living with immune thrombocytopenia (ITP)

Retrieved on: 
Monday, March 15, 2021

florio ITP is a digital diary mobile app developed by Florio GmbH, a Sobi company, in collaboration with ITP patients and healthcare professionals.

Key Points: 
  • florio ITP is a digital diary mobile app developed by Florio GmbH, a Sobi company, in collaboration with ITP patients and healthcare professionals.
  • The florio ITP app is intended to help support patients with ITP with a simple tool that allows them to organize, track and record their health and treatment information.
  • ITP is a rare, autoimmune bleeding disorder that affects approximately 60,000 adults in the United States.
  • "The app embodies Sobi's commitment to support people living with ITP and improve the patient-provider experience."

Panzyga (NEWGAM): A 10% Human Normal Immunoglobulin Solution Ready for Intravenous Administration - Global Emerging Insight and Market Forecast 2021-2030 - ResearchAndMarkets.com

Retrieved on: 
Friday, March 12, 2021

"NEWGAM - Emerging Insight and Market Forecast - 2030" the report provides comprehensive insights about an investigational product for Chronic inflammatory demyelinating Syndromein 7 Major Markets.

Key Points: 
  • "NEWGAM - Emerging Insight and Market Forecast - 2030" the report provides comprehensive insights about an investigational product for Chronic inflammatory demyelinating Syndromein 7 Major Markets.
  • Panzyga (NEWGAM) is a 10% human normal immunoglobulin solution ready for intravenous administration.
  • Panzyga is approved for use in treatment of primary immunodeficiency and idiopathic thrombocytopenic purpura in several countries.
  • Further, it also consists of future market assessments inclusive of the market forecast, SWOT analysis, market competitors, and other emerging therapies.

Global Thrombocytopenia Epidemiology Forecast Report 2018-2030 - ResearchAndMarkets.com

Retrieved on: 
Tuesday, February 23, 2021

The "Thrombocytopenia - Epidemiology Forecast to 2030" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Thrombocytopenia - Epidemiology Forecast to 2030" report has been added to ResearchAndMarkets.com's offering.
  • The disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by Prevalent Cases of Thrombotic Thrombocytopenic Purpura (TTP), Prevalent Cases of Immune Thrombocytopenia (ITP), Prevalent Cases of Thrombocytopenia in Chronic Liver Disease, Incident Cases of Chemotherapy-induced Thrombocytopenia, Number of Cases of Heparin-induced Thrombocytopenia and Total Cases of Thrombocytopenia scenario of Thrombocytopenia in the 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and United Kingdom), and Japan from 2018 to 2030.
  • As per the analysis, the United States accounted for the highest number of Thrombocytopenia cases among the 7MM.
  • The report provides the segmentation of the disease epidemiology for 7MM by Prevalent Cases of Thrombotic Thrombocytopenic Purpura (TTP), Prevalent Cases of Immune Thrombocytopenia (ITP), Prevalent Cases of Thrombocytopenia in Chronic Liver Disease, Incident Cases of Chemotherapy-induced Thrombocytopenia, Number of Cases of Heparin-induced Thrombocytopenia, and Total Cases of Thrombocytopenia.

U.S. FDA Approves PANZYGA® for the Treatment of Adults with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

Retrieved on: 
Friday, February 12, 2021

Most individuals will require long term treatment; nearly a third of CIDP patients will progress to wheelchair dependence if left untreated.

Key Points: 
  • Most individuals will require long term treatment; nearly a third of CIDP patients will progress to wheelchair dependence if left untreated.
  • This Phase 3 study was the first and only IVIg CIDP treatment study to evaluate more than one maintenance dosing option.
  • The primary efficacy endpoint was the proportion of responders in the 1.0 g/kg PANZYGA treatment arm at six months relative to baseline.
  • PANZYGA was approved by the U.S. FDA in 2018 for the treatment of primary immunodeficiency (PI) in patients two years of age and older and chronic immune thrombocytopenia (cITP) in adults.